GlassScriptPhysician profile
Taylor Simmons
NPI 1023572088
$4,317.13
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,862 · 2022: $1,826 · 2023: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.18 | 2021-2023 | |
| Amgen INC. | $363.52 | 2021-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $346.33 | 2021-2023 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $263.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $253.20 | 2021-2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $203.91 | 2021 | |
| Novo Nordisk INC | $169.28 | 2021-2023 | Rybelsus, Ozempic |
| Antares Pharma, INC. | $149.37 | 2021-2022 | |
| Eisai INC. | $121.32 | 2021 | |
| Esperion Therapeutics, INC. | $93.63 | 2021-2023 | Nexletol |
| Horizon Therapeutics Plc | $80.61 | 2022-2023 | Krystexxa |
| Nestle Healthcare Nutrition INC. | $71.77 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $70.93 | 2021-2022 | |
| Pfizer INC. | $68.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $68.44 | 2022-2023 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.